Biomerica (BMRA) said Thursday its Fortel prostate-specific antigen screening test has been approved by the United Arab Emirates Ministry of Health and Prevention for detection of prostate cancer.
The company said the test uses a finger-prick blood sample to measure prostate-specific antigen levels.
The company's shares were up more than 227% in recent Thursday trading.
Price: 1.11, Change: +0.77, Percent Change: +227.23
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.